Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

189
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
189
Antibody Actions01:26

Antibody Actions

1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Principles of Drug Action01:24

Principles of Drug Action

6.0K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.0K
Prodrugs01:30

Prodrugs

2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
2.6K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Antibody Structure01:10

Antibody Structure

60.1K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re-Identification of the Panamanian Guna/Kuna/Cuna OCA2 Founder Association Through Two American-Born Siblings.

American journal of medical genetics. Part A·2026
Same author

Ultra-high tumor mutation burden breast cancer: genomic profiling and real-world immunotherapy results.

NPJ breast cancer·2026
Same author

Contemporary characteristics and outcomes of valve surgery for carcinoid heart disease.

JTCVS open·2026
Same author

Correction to: Microplastic contamination in commercial eyedrop products: detection and characterization study.

Environmental science and pollution research international·2026
Same author

Microplastic contamination in commercial eyedrop products: detection and characterization study.

Environmental science and pollution research international·2026
Same author

Prognostic value of aortic valve calcium score on contrast cardiac computed tomography in patients undergoing transcatheter aortic valve replacement.

Journal of cardiovascular computed tomography·2026

Related Experiment Video

Updated: Jun 27, 2025

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.8K

Antibody-drug conjugates: Principles and opportunities.

Zhi Xin Phuna1, Prashanth Ashok Kumar2, Elio Haroun2

  • 1Research and Development, Medicovestor, Inc, New York City, NY, United States of America.

Life Sciences
|April 30, 2024
PubMed
Summary

Antibody-drug conjugates (ADCs) offer targeted cancer therapy by combining antibodies with cytotoxic agents. This approach aims to enhance tumor cell killing while minimizing chemotherapy side effects.

Keywords:
Antibody-drug conjugatesBackbone antibodiesLinkersPayloads

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K

Related Experiment Videos

Last Updated: Jun 27, 2025

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.8K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Antibody-drug conjugates (ADCs) represent a promising class of cancer therapeutics.
  • ADCs leverage monoclonal antibodies for targeted delivery of potent cytotoxic payloads to tumor cells.
  • This targeted approach aims to improve efficacy and reduce systemic toxicity compared to traditional chemotherapy.

Purpose of the Study:

  • To provide an overview of antibody specificity and ADC structure.
  • To discuss the mechanisms of action and resistance development in ADCs.
  • To explore strategies for enhancing ADC efficacy and overcoming resistance.

Main Methods:

  • Literature review and synthesis of current research on ADCs.
  • Analysis of ADC mechanisms, resistance pathways, and therapeutic advancements.
  • Exploration of future perspectives in ADC development for cancer treatment.

Main Results:

  • ADCs combine antibody specificity with cytotoxic payloads for targeted tumor cell killing.
  • Advances in target identification, payloads, and linkers have expanded ADC therapeutic potential.
  • Understanding resistance mechanisms is crucial for optimizing ADC efficacy.

Conclusions:

  • ADCs offer a targeted approach to cancer treatment with reduced side effects.
  • Continued research into novel targets, payloads, and overcoming resistance is vital for advancing ADC therapy.
  • ADCs hold significant promise for improving outcomes in cancer treatment.